Latest Denise Faustman Stories
Researchers in Cambridge, Mass., found a link between metabolic and immunologic conditions, they said in papers published Sunday in the journal Nature Medicine. They used two over-the-counter allergy medications to reduce both obesity and type 2 diabetes in mice.
In the new issue of the Developmental Cell journal, a team of scientists at Singapore's Agency for Science, Technology and Research (A*STAR) and the University of North Carolina School of Medicine at Chapel Hill
MINNEAPOLIS and ST. PAUL, Minn., Dec. 11 /PRNewswire/ -- The University of Minnesota has received a $40 million pledge for diabetes research from the Richard M. Schulze Family Foundation.
Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.
U.S. scientists say they confirmed in human experiments a potential type 1 diabetes therapy that might reverse the disease. Researchers led by Dr. Denise Faustman, director of the Massachusetts General Hospital's immunobiology laboratory, confirmed the mechanism behind the potential new therapy.
Launching a counter-attack on the immune response that causes insulin-dependent diabetes may provide a revolutionary new way of treating the disease, research has shown.
Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the exact trigger of the attack has been unclear.
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop "Epi-13", a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans.
The spleen may be a source of potential adult stem cells that contain a protein called Hox11, which is associated with embryonic development and limb regeneration in some animals, says a Massachusetts General Hospital study.